{"totalCount":4,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT07178912","orgStudyIdInfo":{"id":"2025-0934"},"secondaryIdInfos":[{"id":"NCI-2025-06675","type":"OTHER","domain":"NCI-CTRP Clinical Registry"}],"organization":{"fullName":"M.D. Anderson Cancer Center","class":"OTHER"},"briefTitle":"Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)","officialTitle":"Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)"},"statusModule":{"statusVerifiedDate":"2025-12","overallStatus":"NOT_YET_RECRUITING","startDateStruct":{"date":"2026-02-27","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-09-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2031-09-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-09-10","studyFirstSubmitQcDate":"2025-09-10","studyFirstPostDateStruct":{"date":"2025-09-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-12-10","lastUpdatePostDateStruct":{"date":"2025-12-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"M.D. Anderson Cancer Center","class":"OTHER"},"collaborators":[{"name":"Amgen","class":"INDUSTRY"},{"name":"Ascentage Pharma Group Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"To find out if giving blinatumomab as injections under the skin and olverembatinib can help to control the disease in patients with Ph-positive ALL.","detailedDescription":"Primary Objective\n\n• To evaluate the rate of complete molecular response (CMR; undetectable BCR::ABL1 transcript by RT-PCR) in participants with newly diagnosed Ph-positive ALL and the overall response rate (complete remission + complete remission with incomplete count recovery) in participants with relapsed/refractory Ph-positive ALL\n\nSecondary Objectives\n\n* To evaluate event-free survival (EFS)\n* To evaluate overall survival (OS)\n* To evaluate MRD negativity by next-generation sequencing (NGS) at a sensitivity of 1x10-6\n* To assess the safety of the regimen"},"conditionsModule":{"conditions":["Phase II Clinical Trial","Blinatumomab","Olverembatinib","Lymphoblastic Leukemia","Philadelphia Chromosome Positive"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":60,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment with Blinatumomab (SC) + Olverembatinib (PO) Q5W","type":"EXPERIMENTAL","description":"Patients will be receiving blinatumomab and olverembatinib.","interventionNames":["Drug: Blinatumomab","Drug: olverembatinib"]}],"interventions":[{"type":"DRUG","name":"Blinatumomab","description":"Given by Iv","armGroupLabels":["Treatment with Blinatumomab (SC) + Olverembatinib (PO) Q5W"]},{"type":"DRUG","name":"olverembatinib","description":"Given by PO","armGroupLabels":["Treatment with Blinatumomab (SC) + Olverembatinib (PO) Q5W"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"safety and adverse events","description":"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0","timeFrame":"Through study completion; an average of 1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Eligibility Criteria\n\n* Diagnosis of one of the following:\n\n  o Participants ≥18 years of age with newly diagnosed or relapsed/refractory Ph-positive and/or BCR::ABL1-positive ALL (includes Participants initiated on first course of therapy before cytogenetics known) or with lymphoid accelerated or blast phase CML. Participants with newly diagnosed disease could have received one or two courses of chemotherapy with or without other TKIs and still eligible (Participants with lymphoid accelerated or blast phase CML will be evaluated separately).\n* Performance status ≤2 (ECOG Scale).\n* Adequate liver function as defined by the following criteria (unless the increased values are judged to be leukemia disease related):\n\n  * Total serum bilirubin \\<2 x upper limit of normal (ULN), unless due to Gilbert's syndrome\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\<3 x ULN.\n* Adequate pancreatic function as defined by serum lipase and amylase \\<1.5 x ULN.\n* For females of childbearing potential, a negative urine pregnancy test must be documented.\n* Female Participants who:\n\n  * Are postmenopausal for at least 1 year before the screening visit, OR\n  * Are surgically sterile, OR\n  * If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug or agree to completely abstain from heterosexual intercourse.\n* Male Participants, even if surgically sterilized (i.e., status post-vasectomy), who:\n\n  * Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, OR\n  * Agree to completely abstain from heterosexual intercourse.\n* Adequate cardiac function as assessed clinically by history and physical examination.\n* Signed informed consent.\n\nExclusion Criteria\n\n* Active serious infection not controlled by oral or IV antibiotics.\n* Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator's opinion will shorten survival to less than 1 year.\n* Participants with psychiatric illness/social situations that would limit compliance with study requirements.\n\nActive grade III-V cardiac failure as defined by the New York Heart Association criteria.\n\n* Uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:\n\n  * Myocardial infarction, stroke, or revascularization within 3 months\n  * Unstable angina or transient ischemic attack\n  * Congestive heart failure prior to enrollment, or left ventricular ejection fraction less than lower limit of normal per local institutional standards prior to enrollment\n  * Diagnosed or suspected congenital long QT syndrome\n  * Clinically significant atrial or ventricular arrhythmias (such as atrial fibrillation, ventricular tachycardia, ventricular fibrillation, or Torsades de pointes) as determined by the treating physician\n  * Prolonged QTc interval on pre-entry electrocardiogram (\\>470 msec) unless corrected after electrolyte replacement or approved by cardiologist\n  * Significant venous or arterial thromboembolism including deep venous thrombosis or pulmonary embolism. Participants with a history of treated prior superficial or catheter associated thrombosis will not be considered as significant embolism and after discussion with PI will not be excluded from eligibility\n  * Uncontrolled hypertension (diastolic blood pressure \\>90 mmHg, systolic \\>140 mmHg). Participants with hypertension should be under treatment on study entry for blood pressure control.\n* History or presence of clinically relevant CNS pathology such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis. Participants with active CNS leukemia will not be excluded.\n* Current autoimmune disease or history of autoimmune disease with potential CNS involvement.\n* Treatment with any investigational antileukemic agent or chemotherapy agent in the last 7 days before study entry, unless full recovery from side effects has occurred or Participant has rapidly progressive disease judged to be life-threatening by the investigator.\n* Pregnant and lactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception. Women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control.\n* History of significant bleeding disorder unrelated to cancer, including:\n\n  * Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)\n  * Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies).\n* Participants with documented significant pleural or pericardial effusions unless they are thought to be secondary to their leukemia.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Elias J Jabbour, MD","role":"CONTACT","phone":"713-792-4764","email":"ejabbour@mdanderson.org"}],"overallOfficials":[{"name":"Elias J Jabbour, MD","affiliation":"M.D. Anderson Cancer Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"MD Anderson Cancer Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","contacts":[{"name":"Elias j Jabbour, MD","role":"CONTACT","phone":"713-792-4764","email":"ejabbour@mdanderson.org"},{"name":"Elias J Jabbour, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":29.76328,"lon":-95.36327}}]},"referencesModule":{"seeAlsoLinks":[{"label":"MD Anderson Cancer Center","url":"http://www.mdanderson.org"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D054198","term":"Precursor Cell Lymphoblastic Leukemia-Lymphoma"}],"ancestors":[{"id":"D007945","term":"Leukemia, Lymphoid"},{"id":"D007938","term":"Leukemia"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D008232","term":"Lymphoproliferative Disorders"},{"id":"D008206","term":"Lymphatic Diseases"},{"id":"D007160","term":"Immunoproliferative Disorders"},{"id":"D007154","term":"Immune System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C510808","term":"blinatumomab"},{"id":"C579813","term":"olverembatinib"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT07013578","orgStudyIdInfo":{"id":"3665"},"organization":{"fullName":"TIDHI Innovation Inc.","class":"OTHER"},"briefTitle":"TIDHI Mental Health in IBD Patients Study","officialTitle":"A Randomized Evaluation of Changes in Anxiety and Depression in Inflammatory Bowel Disease Patients Comparing Structured Mental Health Support to App Based Mental Health Support in Addition to Standard of Care Medical Treatment"},"statusModule":{"statusVerifiedDate":"2025-08","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-07-22","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-07-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-06-02","studyFirstSubmitQcDate":"2025-06-09","studyFirstPostDateStruct":{"date":"2025-06-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-08-05","lastUpdatePostDateStruct":{"date":"2025-08-11","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"TIDHI Innovation Inc.","class":"OTHER"},"collaborators":[{"name":"Amgen","class":"INDUSTRY"},{"name":"Celltrion","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to test the impact of Healing Circuits™; a structured mental health support model on IBD patients. The eligible study participants will be randomly divided into two groups: 1. the group receiving structured mental health support with a social worker and 2. the group receiving structured mental health support via a self-directed online curriculum. Both groups will be receiving the same type of therapy, Healing Circuits™, but the group receiving the therapy via the online self-directed curriculum will be receiving the therapy mostly by web-based video instruction. The two groups will be evaluated over a period of 12 months."},"conditionsModule":{"conditions":["Crohn Disease (CD)","Ulcerative Colitis (UC)","Inflammatory Bowel Disease (IBD)"],"keywords":["Healing Circuits"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":100,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Sessions with a social worker based on Healing Circuits™ Methodology","type":"EXPERIMENTAL","interventionNames":["Behavioral: Healing Circuits™ sessions"]},{"label":"Online modules of a self-directed Healing Circuits™ curriculum","type":"EXPERIMENTAL","interventionNames":["Behavioral: self-directed Healing Circuits™ curriculum"]}],"interventions":[{"type":"BEHAVIORAL","name":"Healing Circuits™ sessions","description":"Treatment of the Study group will involve 12-weekly 50-minute sessions with a social worker who has been trained in the Healing Circuits™ Methodology - a structured mental health support delivered by a therapist in a one-on-one model.","armGroupLabels":["Sessions with a social worker based on Healing Circuits™ Methodology"]},{"type":"BEHAVIORAL","name":"self-directed Healing Circuits™ curriculum","description":"Treatment of the Control group will involve 12 weekly online modules of a self-directed Healing Circuits™ curriculum - structured mental health support being delivered in an web-based video instruction model.","armGroupLabels":["Online modules of a self-directed Healing Circuits™ curriculum"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Generalized Anxiety Disorder 7-item Scale (GAD-7) Score","description":"The Generalized Anxiety Disorder Assessment (GAD7) is a seven-item instrument that is used to measure or assess the severity of generalized anxiety disorder (GAD). Each item asks the individual to rate the severity of his or her symptoms over the past two weeks. Scores range from 0 to 21, with higher scores indicating greater anxiety.\n\nThis outcome will compare the mean change in GAD-7 scores from baseline between participants receiving one-on-one therapy and those receiving app-based therapy.","timeFrame":"3 months following initiation of Healing Circuits™"},{"measure":"Time to Improvement in Generalized Anxiety Disorder 7-item Scale (GAD-7) Score","description":"Improvement is defined as a ≥2-point reduction from baseline in GAD-7 score. The outcome will compare the time (months ) it takes participants in the one-on-one therapy group and the app-based therapy group to reach this level of improvement.","timeFrame":"3 months following initiation of Healing Circuits™"},{"measure":"Change in Patient Health Questionnaire-9 (PHQ-9) Score","description":"PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores range from 0 to 27, with higher scores indicating greater depression severity.\n\nThis outcome will assess the mean difference in PHQ-9 scores between the one-on-one therapy and app-based therapy groups.","timeFrame":"3 months following initiation of Healing Circuits™"},{"measure":"Time to Improvement in Patient Health Questionnaire-9 (PHQ-9) Score","description":"Improvement is defined as a ≥2-point reduction from baseline in PHQ-9 score. This outcome compares the time (months ) it takes for participants in the one-on-one therapy group and the app-based therapy group to reach the improvement threshold.","timeFrame":"3 months following initiation of Healing Circuits™"}],"secondaryOutcomes":[{"measure":"Proportion of Participants Achieving at Least a 2-Point Reduction in GAD-7 Score","description":"This outcome measures the proportion of participants who experience a reduction of at least 2 points in the GAD-7 (range: 0-21, higher scores = worse anxiety) at 6, 9, and 12 months after beginning the Healing Circuits™ intervention.","timeFrame":"6, 9, and 12 months following initiation of Healing Circuits™"},{"measure":"Proportion of Participants Achieving at Least a 2-Point Reduction in PHQ-9 Score","description":"6, 9, and 12 months following initiation of Healing Circuits™","timeFrame":"This outcome measures the proportion of participants who experience a reduction of at least 2 points in the PHQ-9 (range: 0-27, higher scores = worse depression) at 6, 9, and 12 months after beginning the Healing Circuits™ intervention."},{"measure":"Mean Change in 36-Item Short Form Survey (SF-36) Score Between Groups","description":"This outcome measures the mean difference in scores on the SF-36, a 36-item, patient-reported survey of patient health. Each item is scored out of 100 and a higher score is correlated to more favorable health. It addresses 8 health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions.\n\nThe comparison will be made between the one-on-one therapy group and the app-based therapy group at the specified time points.","timeFrame":"3, 6, 9, and 12 months following initiation of Healing Circuits™"},{"measure":"Mean Change in Patient Satisfaction Score on a Likert Scale Between Groups","description":"This outcome measures the mean difference in patient satisfaction between the one-on-one therapy group and the app-based therapy group. Satisfaction is assessed using a custom 10-point Likert scale ranging from 1 (Worst Possible Experience) to 10 (Best Possible Experience), with higher scores indicating greater satisfaction.","timeFrame":"3, 6, 9, and 12 months following initiation of Healing Circuits™"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nSubjects must meet each of the following criteria for enrolment into the study:\n\n1. Written informed consent must be obtained and documented.\n2. Males and females between the ages of 18 and 75 years of age with documented diagnosis of IBD.\n3. GAD7 and/or PHQ9 score of 10 - 15.\n4. Ability of subject to participate fully in all aspects of this clinical trial.\n5. IBD patients who plan to have ongoing medical care at TIDHI.\n\nExclusion Criteria:\n\nSubjects who exhibit any of the following conditions are to be excluded from the study:\n\n1. Plan for change in systemically delivered IBD-related medical therapy in the 3 months after screening.\n2. Serious underlying psychiatric disorder such as schizophrenia or bipolar disorder.\n3. Planned change in psychiatric medication, if any is being taken, within 3 months after screening.\n4. History of illegal drug abuse (excluding marijuana) or alcohol abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Ajani Jeyakumar, HBSc BScN RN","role":"CONTACT","phone":"647-812-2113","email":"ajeyakumar@tidhi.ca"}],"overallOfficials":[{"name":"Mark Silverberg, MD, PhD","affiliation":"TIDHI Innovation Inc.","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Marci Reiss, DSW","affiliation":"TIDHI Innovation Inc.","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Toronto Immune and Digestive Health Institute","status":"RECRUITING","city":"North York","state":"Ontario","zip":"M6A 3B4","country":"Canada","contacts":[{"name":"Ajani Jeyakumar","role":"CONTACT","phone":"647-812-2113","email":"ajeyakumar@tidhi.ca"}]}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D003424","term":"Crohn Disease"},{"id":"D003093","term":"Colitis, Ulcerative"},{"id":"D015212","term":"Inflammatory Bowel Diseases"}],"ancestors":[{"id":"D005759","term":"Gastroenteritis"},{"id":"D005767","term":"Gastrointestinal Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D007410","term":"Intestinal Diseases"},{"id":"D003092","term":"Colitis"},{"id":"D003108","term":"Colonic Diseases"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT05074810","orgStudyIdInfo":{"id":"VS-6766-203"},"organization":{"fullName":"Verastem, Inc.","class":"INDUSTRY"},"briefTitle":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients","officialTitle":"A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)","acronym":"RAMP203"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-04-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-04","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-09-29","studyFirstSubmitQcDate":"2021-09-29","studyFirstPostDateStruct":{"date":"2021-10-12","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-08","lastUpdatePostDateStruct":{"date":"2026-01-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Verastem, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Amgen","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.","detailedDescription":"This is a multicenter, non-randomized, open-label Phase 1/2 study designed to evaluate safety and tolerability and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C mutant NSCLC."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer","KRAS Activating Mutation"],"keywords":["NSCLC","KRAS G12C"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":153,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"avutometinib (VS-6766)+sotorasib","type":"EXPERIMENTAL","description":"To determine the recommended phase 2 dose (RP2D) for avutometinib (VS 6766) in combination with sotorasib in KRAS G12C inhibitor naïve and exposed patients","interventionNames":["Drug: avutometinib and sotorasib"]},{"label":"avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor naïve","type":"EXPERIMENTAL","description":"To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor naïve patients","interventionNames":["Drug: avutometinib and sotorasib"]},{"label":"avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor exposed","type":"EXPERIMENTAL","description":"To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor exposed patients","interventionNames":["Drug: avutometinib and sotorasib"]},{"label":"avutometinib (VS-6766)+sotorasib+defactinib","type":"EXPERIMENTAL","description":"To determine the recommended phase 2 dose (RP2D) for avutometinib (VS-6766) in combination with sotorasib and defactinib in KRAS G12C inhibitor exposed patients","interventionNames":["Drug: avutometinib and sotorasib and defactinib"]},{"label":"avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor naive","type":"EXPERIMENTAL","description":"To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor naïve patients","interventionNames":["Drug: avutometinib and sotorasib and defactinib"]},{"label":"avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor exposed","type":"EXPERIMENTAL","description":"To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor exposed patients","interventionNames":["Drug: avutometinib and sotorasib and defactinib"]}],"interventions":[{"type":"DRUG","name":"avutometinib and sotorasib","description":"The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion","armGroupLabels":["avutometinib (VS-6766)+sotorasib","avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor exposed","avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor naïve"],"otherNames":["AMG 510","LUMAKRAS™","VS-6766"]},{"type":"DRUG","name":"avutometinib and sotorasib and defactinib","description":"The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion","armGroupLabels":["avutometinib (VS-6766)+sotorasib+defactinib","avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor exposed","avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor naive"],"otherNames":["AMG 510","LUMAKRAS™","VS-6766","VS-6063"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part A: To determine RP2D for avutometinib in combination with sotorasib and the Alt-RP2D for avutometinib in combination with sotorasib and defactinib","description":"Assessment of Dose-limiting toxicities (DLTs)","timeFrame":"From start of treatment to confirmation of RP2D; 28 days"},{"measure":"Part B: To determine the efficacy of the RP2D and/or Alt-RP2D identified from Part A","description":"Confirmed overall response rate per RECIST 1.1","timeFrame":"From start of treatment to confirmation of response; 16 weeks"}],"secondaryOutcomes":[{"measure":"Frequency and severity adverse events (AEs) and Serious Adverse Events (SAEs)","description":"Count of AE and SAEs by grade, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grading scale","timeFrame":"24 months"},{"measure":"Duration of Response (DOR)","description":"Time of first response to PD as assessed per RECIST 1.1","timeFrame":"Time from the first documentation of response to first documentation of progressive disease or death due to any cause, greater than or equal to 6 months"},{"measure":"Disease Control Rate (DCR)","description":"CR and PR stable disease as assessed per RECIST 1.1","timeFrame":"Greater than or equal to 8 weeks"},{"measure":"Progression Free Survival (PFS)","description":"From the time of first dose of study intervention to PD or death from any cause","timeFrame":"24 months"},{"measure":"Overall Survival (OS)","description":"From time of first dose of study intervention to death","timeFrame":"Up to 5 years"},{"measure":"Plasma Pharmacokinetics (PK) of avutometinib, sotorasib, defactinib and relevant metabolites - Tmax","description":"time of Maximum concentration (Tmax)","timeFrame":"10 weeks"},{"measure":"Plasma Pharmacokinetics (PK) of avutometinib, sotorasib, defactinib and relevant metabolites -AUC","description":"Area under plasma Concentration (AUC) 0 to t","timeFrame":"10 weeks"},{"measure":"Plasma Pharmacokinetics (PK) of avutometinib, sotorasib, defactinib and relevant metabolites half-life","description":"concentration Half-life (T1/2)","timeFrame":"10 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patients ≥ 18 years of age\n* Histologic or cytologic evidence of NSCLC\n* Known KRAS G12C mutation\n* Either exposed or not exposed to a KRAS inhibitor to be included in Part A (avutometinib + sotorasib + defactinib) and not exposed to KRAS inhibitor to be included in Part B (avutometinib + sotorasib + defactinib), Cohort 1\n* Received at least 1 dose of a G12C inhibitor to be included in Part B, Cohort 2 (avutometinib + sotorasib + defactinib)\n* Must have received appropriate treatment with at least one prior systemic regimen, but no more than 2 prior regimens, for Stage 3B-C or 4 NSCLC\n* Measurable disease according to RECIST 1.1\n* An Eastern Cooperative Group (ECOG) performance status ≤ 1\n* Adequate organ function\n* Adequate recovery from toxicities related to prior treatments\n* Agreement to use highly effective method of contraceptive\n\nExclusion Criteria:\n\n* Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy\n* History of prior malignancy, with the exception of curatively treated malignancies\n* Major surgery within 4 weeks, minor surgery within 2 weeks (excluding placement of vascular access)\n* History of treatment with a direct and specific inhibitor of MEK\n* Exposure to strong CYP3A4 inhibitors or inducers within 14 days prior to the first dose and during the course of therapy\n* Symptomatic brain metastases requiring steroids or other local interventions.\n* Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy\n* Known hepatitis B, hepatitis C, or human immunodeficiency virus infection that is active\n* Active skin disorder that has required systemic therapy within the past year\n* History of rhabdomyolysis\n* Concurrent ocular disorders\n* Concurrent heart disease or severe obstructive pulmonary disease\n* Inability to swallow oral medications\n* Female patients that are pregnant or breastfeeding\n* Previously treated with sotorasib and were dose reduced due to toxicity","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"MD Verastem","affiliation":"Verastem, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Rocky Mountain Cancer Center, LLP","city":"Boulder","state":"Colorado","zip":"80303","country":"United States","geoPoint":{"lat":40.01499,"lon":-105.27055}},{"facility":"Georgetown University Medical Center","city":"Washington D.C.","state":"District of Columbia","zip":"20007","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"MedStar Washington Hospital Center, MedStar Georgetown Cancer Institute,","city":"Washington D.C.","state":"District of Columbia","zip":"20010","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Illinois Cancer Specialists","city":"Arlington Heights","state":"Illinois","zip":"60005","country":"United States","geoPoint":{"lat":42.08836,"lon":-87.98063}},{"facility":"Maryland Oncology & Hematology, P.A.","city":"Rockville","state":"Maryland","zip":"20850","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"Dana Farber Cancer Institute","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Henry Ford Health System","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Minnesota Oncology Hematology, P.A","city":"Woodbury","state":"Minnesota","zip":"55125","country":"United States","geoPoint":{"lat":44.92386,"lon":-92.95938}},{"facility":"Washington University School of Medicine","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Cleveland Clinic Taussig Cancer Center","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Ohio State University Brain and Spine Hospital","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Consultants in Medical Oncology & Hematology","city":"Broomall","state":"Pennsylvania","zip":"19008","country":"United States","geoPoint":{"lat":39.9815,"lon":-75.35658}},{"facility":"Alliance Cancer Specialists,","city":"Horsham","state":"Pennsylvania","zip":"19044","country":"United States","geoPoint":{"lat":40.17844,"lon":-75.12851}},{"facility":"Texas Oncology","city":"Austin","state":"Texas","zip":"78731","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"University of Texas Southwestern Medical Center","city":"Dallas","state":"Texas","zip":"75390","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Texas Oncology - Fort Worth Cancer Center","city":"Fort Worth","state":"Texas","zip":"76104","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"Texas Oncology","city":"Longview","state":"Texas","zip":"75601","country":"United States","geoPoint":{"lat":32.5007,"lon":-94.74049}},{"facility":"Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care","city":"Blacksburg","state":"Virginia","zip":"24060","country":"United States","geoPoint":{"lat":37.22957,"lon":-80.41394}},{"facility":"Virginia Cancer Specialists, PC","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"facility":"Northwest Cancer Specialists","city":"Vancouver","state":"Washington","zip":"98684","country":"United States","geoPoint":{"lat":45.63873,"lon":-122.66149}},{"facility":"University Hospital Gent","city":"Ghent","zip":"9000","country":"Belgium","geoPoint":{"lat":51.05,"lon":3.71667}},{"facility":"CHU de Liège","city":"Liège","zip":"4000","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"facility":"CHRU of Lille","city":"Lille","zip":"59037","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"Hôpital Cochin","city":"Paris","zip":"75014","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Hôpital Foch","city":"Suresnes","zip":"92150","country":"France","geoPoint":{"lat":48.87143,"lon":2.22929}},{"facility":"Leids Universitair Medisch Centrum","city":"Leiden","zip":"2333 ZA","country":"Netherlands","geoPoint":{"lat":52.15833,"lon":4.49306}},{"facility":"Erasmus MC","city":"Rotterdam","zip":"3015 GD","country":"Netherlands","geoPoint":{"lat":51.9225,"lon":4.47917}},{"facility":"Hospital Teresa Herrera (C.H.U.A.C)","city":"A Coruña","zip":"15006","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Hospital General Universitario Gregorio Marañón","city":"Madrid","zip":"28007","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario Fundación Jiménez Díaz","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario Virgen De La Victoria","city":"Málaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Hospital Universitario Virgen de la Macarena","city":"Seville","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"University of Leicester","city":"Leicester","zip":"LE2 7LX","country":"United Kingdom","geoPoint":{"lat":52.6386,"lon":-1.13169}},{"facility":"Royal Marsden Hospital","city":"London","zip":"SW3 6JJ","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Royal Marsden Hospital","city":"Sutton","zip":"SM2 5PT","country":"United Kingdom","geoPoint":{"lat":51.35,"lon":-0.2}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000706028","term":"sotorasib"},{"id":"C584510","term":"defactinib"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06068153","orgStudyIdInfo":{"id":"ETOP 24-22"},"organization":{"fullName":"ETOP IBCSG Partners Foundation","class":"NETWORK"},"briefTitle":"AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC","officialTitle":"A Multicentre, Single-arm Phase II Trial of Sotorasib Plus Lenvatinib, As Second-line Treatment in Patients with KRASG12C-mutant, Metastatic NSCLC","acronym":"AMBER"},"statusModule":{"statusVerifiedDate":"2024-11","overallStatus":"WITHDRAWN","whyStopped":"In view of the recent developments in the field (the increasing number of trials with new KRAS inhibitors), the window of opportunity to answer the question raised in the AMBER trial was missed.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-03","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-09-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-09-28","studyFirstSubmitQcDate":"2023-09-28","studyFirstPostDateStruct":{"date":"2023-10-05","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-11-18","lastUpdatePostDateStruct":{"date":"2024-11-20","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"ETOP IBCSG Partners Foundation","class":"NETWORK"},"collaborators":[{"name":"Amgen","class":"INDUSTRY"},{"name":"Eisai Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"AMBER is a multicentre, single-arm phase II trial. The protocol treatment consists of of sotorasib plus lenvatinib, as a second-line treatment. The primary objective of the trial is to evaluate the clinical efficacy of sotorasib plus lenvatinib, in terms of objective response rate, for patients with KRASG12C-mutant, metastatic NSCLC."},"conditionsModule":{"conditions":["Metastatic Non Small Cell Lung Cancer","KRAS G12C"],"keywords":["Metastatic NSCLC","KRAS G12C","Sotorasib","Lenvatinib"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":0,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment Arm","type":"EXPERIMENTAL","description":"Sotorasib + Lenvatinib","interventionNames":["Drug: Sotorasib","Drug: Lenvatinib"]}],"interventions":[{"type":"DRUG","name":"Sotorasib","description":"Sotorasib is administered at a dose of 960 mg (8x 120 mg) orally, once daily until progression or unacceptable toxicity.","armGroupLabels":["Treatment Arm"]},{"type":"DRUG","name":"Lenvatinib","description":"Lenvatinib is administered at a dose of 20 mg orally (2x 10 mg), once daily until progression or unacceptable toxicity.","armGroupLabels":["Treatment Arm"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Objective response rate (ORR)","description":"ORR is defined as the rate of patients, among all enrolled patients, achieving a best overall response \\[complete response (CR) or partial response (PR)\\] according to RECIST v1.1, investigator assessed, by 18 weeks post-enrolment.","timeFrame":"From date of enrolment until 18 weeks post-enrolment."}],"secondaryOutcomes":[{"measure":"Progression-free survival per RECIST v1.1","description":"PFS is defined as the time from the date of enrolment until the date of documented progression (according to RECIST v1.1) or death from any cause, if progression is not documented. Censoring (for patients without progression or death) will occur at the date of last tumour assessment. Patients without a post-baseline tumour assessment will be censored at the date of enrolment plus 1 day.","timeFrame":"From the date of enrolment until last tumour assessment (approximately 22 months after the enrolment of the first patient)"},{"measure":"Disease control rate per RECIST v1.1","description":"DCR is defined as the rate of patients, among all enrolled patients, that achieve CR or PR or disease stabilisation (according to RECIST v1.1, investigator assessed) at 18 weeks.","timeFrame":"From date of enrolment until 18 weeks post-enrolment."},{"measure":"Overall survival","description":"OS is defined as the time from the date of enrolment until the date of death from any cause. Censoring (for patients who are not reported as dead) will occur at the date last known to be alive. Data for patients who do not have post-baseline information will be censored at the date of enrolment plus 1 day.","timeFrame":"From the date of enrolment until death from any cause (up to 22 months after the enrolment of the first patient)"},{"measure":"Duration of response","description":"DoR is defined as the interval from the date of first documentation of objective response (CR or PR, according to RECIST v1.1) to the date of first documented progression/relapse or death from any cause.","timeFrame":"From the date of enrolment until last tumour assessment or death from any cause (approximately 22 months after the enrolment of the first patient)"},{"measure":"Adverse events according to CTCAE v5.0","description":"All safety parameters will be summarised in tables in order to evaluate the toxicity and safety profile of the protocol treatment based on:\n\n* Adverse events (AEs) according to CTCAE v5.0 (any-cause as well as treatment-related) including AEs leading to dose delays and/or interruptions, withdrawal of protocol treatment, and death\n* Severe, serious, and selected AEs\n* Deaths\n* Clinically significant laboratory parameters and abnormalities, and vital signs.","timeFrame":"[Time Frame: From the date of enrolment until last patient last visit (approximately 22 months after enrolment of the first patient)]"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pathologically documented metastatic NSCLC.\n* Documented disease progression on prior treatment. Prior treatment must have included platinum-based doublet chemotherapy and immune-checkpoint inhibition.\n* KRASG12C-mutation (identified through local molecular testing, using a validated test).\n* Measurable disease per RECIST v1.1 criteria.\n* Age ≥18 years.\n* ECOG Performance Status of 0-1.\n* Life expectancy of \\>3 months.\n* Ability to swallow oral medications and willing to complete a treatment diary.\n* Adequate haematological function.\n* Adequate renal function.\n* Adequate liver function.\n* Men and women of childbearing potential must use highly effective contraception.\n* Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test within 5 weeks before enrolment. Pregnancy test must be repeated within 3 days before the first dose of protocol treatment.\n* Written IC for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.\n\nExclusion Criteria:\n\n* Active brain metastases E.g., untreated brain lesions (new or progressing) and/or symptomatic brain lesions (symptoms as determined by the investigator).\n\nPatients who have had brain metastases resected or have received whole brain radiation therapy ending at least 4 weeks (or stereotactic radiosurgery ending at least 2 weeks) prior to enrolment are eligible if they meet all of the following criteria:\n\n* Residual neurological symptoms are only of grade ≤2\n* On stable doses of dexamethasone or equivalent for at least 2 weeks, if applicable.\n* History or presence of haematological malignancies. Exception: curatively treated haematological malignancies with no disease evidence in the last 2 years.\n* History of (non-infectious) pneumonitis that required steroids or evidence of ILD/pneumonitis.\n* Active hepatitis B and C and uncontrolled HIV.\n* Uncontrolled blood pressure (systolic blood pressure \\>150 mmHg or diastolic blood pressure \\>90 mmHg) in spite of an optimised regimen of antihypertensive medication.\n* Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, long QT syndrome (LQTS), unstable angina, myocardial infarction or stroke within 6 months before enrolment, or cardiac arrhythmia requiring medical treatment at screening\n* Bleeding or thrombotic disorders or patients at risk for severe haemorrhage. The degree of tumour invasion/infiltration of major blood vessels (e.g. carotid artery) should be considered because of the potential risk of severe haemorrhage associated with tumour shrinkage/necrosis following lenvatinib therapy.\n* Current or recent (within 10 days of enrolment) use of aspirin (\\>325 mg/day) or treatment with dipyramidole, ticlopidine, clopidogrel, or clostazol.\n* Electrolyte abnormalities that have not been corrected.\n* Proteinuria on urine dipstick testing \\>1+, unless a 24-hour urine collection for quantitative assessment indicates that the urine protein is \\<2 g/24 hours.\n* History of abdominal or tracheoesophageal fistula or gastrointestinal perforation within 6 months prior to inclusion.\n* Unresolved toxicities from previous lines of anti-cancer treatment regimens and/or (with the exception of alopecia) complications from major surgery prior to enrolment.\n* Previous treatment with KRAS- and/or VEGF/R inhibitors.\n* Hypersensitivity to sotorasib or lenvatinib.\n* Women who are pregnant or breastfeeding or who are planning to become pregnant or breastfeed.\n* Sexually active men and women of childbearing potential who are not willing to use a highly effective contraceptive method during the trial and for 7 days after the last dose of sotorasib and until 30 days after the last dose of lenvatinib.\n* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Alfredo Addeo","affiliation":"Département d'Oncologie Hôpitaux Universitaires de Genève","role":"STUDY_CHAIR"},{"name":"Sanjay Popat","affiliation":"Royal Marsden NHS Foundation Trust","role":"STUDY_CHAIR"}],"locations":[{"facility":"Medical University of Innsbruck / UK für Innere Medizin V","city":"Innsbruck","country":"Austria","geoPoint":{"lat":47.26266,"lon":11.39454}},{"facility":"University Hospital of Munich (LMU), Department of Medicine V (Pneumology/Thoracic Oncology)","city":"Munich","country":"Germany","geoPoint":{"lat":48.13743,"lon":11.57549}},{"facility":"Alicante University Dr Balmis Hospital ISABIAL","city":"Alicante","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Ico Badalona - Hospital Germans Trias I Pujol","city":"Badalona","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"Hospital Universitario Lucus Augusti","city":"Lugo","country":"Spain","geoPoint":{"lat":43.00992,"lon":-7.55602}},{"facility":"Hospital Universitario de Salamanca","city":"Salamanca","country":"Spain","geoPoint":{"lat":40.42972,"lon":-3.67975}},{"facility":"Hospital Universitario Nuestra Señora de Candelaria","city":"Santa Cruz de Tenerife","country":"Spain","geoPoint":{"lat":28.46824,"lon":-16.25462}},{"facility":"Hospital Universitario Virgen Del Rocio","city":"Seville","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Universitario de Toledo","city":"Toledo","country":"Spain","geoPoint":{"lat":39.8581,"lon":-4.02263}},{"facility":"Hospital Universitario Y Politécnico La Fe","city":"Valencia","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Istituto Oncologico della Svizzera Italiana","city":"Bellinzona","country":"Switzerland","geoPoint":{"lat":46.19278,"lon":9.01703}},{"facility":"Kantonsspital Graubünden","city":"Chur","country":"Switzerland","geoPoint":{"lat":46.84986,"lon":9.53287}},{"facility":"HFR Fribourg","city":"Fribourg","country":"Switzerland","geoPoint":{"lat":46.80237,"lon":7.15128}},{"facility":"HUG","city":"Geneva","country":"Switzerland","geoPoint":{"lat":46.20222,"lon":6.14569}},{"facility":"Kantonsspital Winterthur","city":"Winterthur","country":"Switzerland","geoPoint":{"lat":47.50564,"lon":8.72413}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","infoTypes":["STUDY_PROTOCOL","SAP"]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000706028","term":"sotorasib"},{"id":"C531958","term":"lenvatinib"}]}},"hasResults":false}
]}